Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“EMERALD-1 and EMERALD-3 discussion ESMO GI 2026
- PFS alone may not be enough
- OS remains the key endpoint
- Patient selection, early mortality, toxicity and post-TACE treatment sequencing matter.
The role of IO + TACE continues to evolve.”
Other articles featuring Nieves Martinez Lago on OncoDaily.
